ClosedResearch announcementOpportunity HT942526ALSRPTDA

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Defense Health Agency Contracting Activity - DHACA · Department of Defense

At a glance

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is a closed federal grant opportunity from the Defense Health Agency Contracting Activity - DHACA (Department of Defense). The application deadline was September 30, 2026. Total estimated funding is $12M across about 6 awards. The notice is unrestricted by applicant type, subject to any clarifications in the notice. Cost sharing is not required. It is funded under Assistance Listing 12.420 (Military Medical Research and Development).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

May 4, 2026Posted
Sep 30, 2026Application deadline
Oct 30, 2026Archivednext date

Posted: May 4, 2026
Close date: Sep 30, 2026
Archive date: Oct 30, 2026
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: $12,000,000
Implied average award: $2,000,000 calculated
Expected awards: 6
Cost sharing: Not required
Funding instrument: Grant
Opportunity category: Discretionary

Typical awards for this program (SAM.gov listing for ALN 12.420, not this notice): This Assistance Listing supports approximately 30 or more programs each year. Overall, awards are expected to range from $100,000 to $20M (consortium) depending on the funding priorities, anticipated number of awards, and project activity/scope within each program for an award period, on average, of 3 to 4 years. The maximum award amount, if any, is specified in each Program Announcement or Broad Agency Announcement.

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

Unrestricted (any entity type)

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.

Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.

Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.

Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

FY26 ALSRP TDA Program AnnouncementFull Announcement · HT942526ALSRPTDA_GG.pdfPDF · 713 KB

Assistance Listing

What is an ALN?

12.420Military Medical Research and DevelopmentProgram →

Reported obligations under ALN 12.420

Historical data · not a prediction

FY24

$1.48B

FY25

$1.2B

FY26

— est.

Source: SAM.gov Assistance Listing 12.420. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Jamie Shortall Grant Officer
help@eBRAP.org
301-619-2393

Quick answers

Who is eligible to apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award”?

The notice lists eligibility as unrestricted — open to any type of entity — subject to clarifications in the notice's additional eligibility information.

How much funding is available through “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award”?

Per the notice, total estimated program funding is $12,000,000 and the agency expects to make about 6 awards.

How do I apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity HT942526ALSRPTDA), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

Closes in 5 daysResearchALN 12.420